Ceterizine

Phase 2Small molecule

Ceterizine is one of 4 small molecule programs targeting Metastatic HR+/HER2- Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic HR+/HER2- Breast CancerRecruiting

Metastatic HR+/HER2- Breast CancerPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Metastatic HR+/HER2- Breast Cancer

#DrugCompanyPhaseTrials

Truqap

AstraZeneca

Phase 2

1 2

Imodium

KKenvue Brands

Phase 2

1 3

Faslodex

FFresenius Kabi USA, LLC

Phase 2

1 4

Ceterizine

Sanofi

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Recruiting

Metastatic HR+/HER2- Breast Cancer

NCT07426822

Clinical

Trials by Indication[1]

Multiple Sclerosis2 trials

A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis

Completed· Sanofi logo

Sanofi·Phase 1·NCT02583594·24 enrolled

A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Paediatric Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Disease Activity on Prior Disease Modifying Therapy (DMT)

Terminated· Sanofi logo

Sanofi·Phase 3·NCT03368664·16 enrolled

Metastatic HR+/HER2- Breast Cancer1 trial

A Phase II Trial to Improve Safety of Capivasertib for HR+/HER2- Metastatic Breast Cancer

Recruiting·MMaryam Lustberg·Phase 2·NCT07426822·108 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Ceterizine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ceterizine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ceterizine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Sanofi

Ceterizine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Multiple Sclerosis2 trials

Metastatic HR+/HER2- Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News